Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Rain Therapeutics stock
Learn how to easily invest in Rain Therapeutics stock.
Rain Therapeutics is a biotechnology business based in the US. Rain Therapeutics shares (RAIN) are listed on the NASDAQ and all prices are listed in US Dollars. Rain Therapeutics employs 63 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy Rain Therapeutics stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – RAIN. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Easy to use platform with $0 stock trading & no annual fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
Rain Therapeutics stock price (NASDAQ: RAIN)Use our graph to track the performance of RAIN stocks over time.
Rain Therapeutics shares at a glance
|Latest market close||$8.50|
|52-week range||$2.15 - $14.48|
|50-day moving average||$9.26|
|200-day moving average||$6.86|
|Wall St. target price||$18.18|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-2.92|
Buy Rain Therapeutics stocks from these online trading platformsCompare special offers, low fees and a wide range of investment options among top trading platforms.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy Rain Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Rain Therapeutics price performance over time
Historical closes compared with the close of $8.5 from 2023-03-24
|1 week (2023-03-17)||8.42%|
|1 month (2023-02-24)||8.5|
|3 months (2022-12-23)||30.97%|
|6 months (2022-09-26)||30.97%|
|1 year (2022-03-25)||47.31%|
|2 years (2021-03-22)||N/A|
|3 years (2020-03-23)||37.99%|
|5 years (2018-03-22)||N/A|
Rain Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-34.15%|
|Return on equity TTM||-62.19%|
|Market capitalisation||$313.8 million|
TTM: trailing 12 months
Rain Therapeutics share dividends
We're not expecting Rain Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
- Bristol-Myers Squibb Company (BMY.US) (3.39% forward annual dividend yield)
Rain Therapeutics overview
Rain Oncology Inc. , a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States. The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc.
Rain Therapeutics in the news
Rain Oncology Announces Oral Presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress
Rain Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
Rain Oncology to Present At Oppenheimer 33rd Annual Healthcare Conference
Frequently asked questionsWhat percentage of Rain Therapeutics is owned by insiders or institutions?
Currently 14.847% of Rain Therapeutics shares are held by insiders and 87.543% by institutions. How many people work for Rain Therapeutics?
Latest data suggests 63 work at Rain Therapeutics. When does the fiscal year end for Rain Therapeutics?
Rain Therapeutics's fiscal year ends in December. Where is Rain Therapeutics based?
Rain Therapeutics's address is: 8000 Jarvis Avenue, Newark, CA, United States, 94560 What is Rain Therapeutics's ISIN number?
Rain Therapeutics's international securities identification number is: US75082Q1058
More guides on Finder
What happens if a brokerage firm fails?
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
How to buy gold
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Silicon Valley Bank collapse: Which ETFs and stocks are impacted?
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
How to Buy Treasury Bills
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
SVB collapses: What does it mean for your portfolio?
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
How to buy Vanguard VTI Total Stock Market ETF units
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
Ask an Expert